About: http://data.cimple.eu/news-article/a3f9a1c38589f641b66d53c919dea769cee7b65179defebe05249c1d

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/a3f9a1c38589f641b66d53c919dea769cee7b65179defebe05249c1d Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pharmaceutical giant AstraZeneca on Tuesday revealed it had hit a setback in trials of a treatment for Covid-19 symptoms. The drug, made from a combination of two antibodies, failed its main goal to treat symptoms in exposed patients, the company said in a statement. The treatment has been undergoing phase 3 or final-stage clinical trials to assess its safety and efficacy. AstraZeneca said that 1,121 unvaccinated adults had been exposed to an infected person as part of the trial. Treatment AZD7442 reduced the risk of developing symptoms by only 33 percent -- which was "not statistically significant", it added. The company is nevertheless continuing trials to assess whether the drug can prevent Covid or treat more severe symptoms. The US government has funded the development of AZD7442 and has agreements to receive 700,000 doses. Meanwhile, AstraZeneca's Covid vaccine, which was developed with the University of Oxford, faced fresh safety doubts. The jab has been suspended in several European countries over reports of rare blood clots. A top official in the European Medicines Agency was on Sunday reported as having suggested that it might be worth abandoning AstraZeneca's vaccine if alternatives were available. But the EMA said the body's head of vaccine strategy, Marco Cavaleri, had been misrepresented, and that he believed its benefits outweigh its risks. "The decision on its use in different populations and ages is the prerogative of the EU Member States, based on specific factors such as virus circulation and vaccine availability," a spokeswoman said. A study from British health authorities published on Monday found that two doses of AstraZeneca/Oxford or rival Pfizer/BioNTech vaccines stopped the need for in-patient treatment in more than 90 percent of cases of the Delta variant. The UK government on Monday announced a four-week delay to the full lifting of coronavirus restrictions in England due to a surge in infections caused by Delta, which first appeared in India. jbo-rfj/phz/tgb
schema:headline	AstraZeneca hits snag in Covid drug development
schema:mentions	European Medicines Agency Hertz Jab University of Oxford Delta Air Lines AstraZeneca European Union Virus Pfizer India Coronavirus disease United Kingdom Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Venous thrombosis Drug development Monoclonal antibody
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-06-15 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	80 (xsd:integer)

Faceted Search & Find service v1.16.123 as of May 22 2025

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3241 as of May 22 2025, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 8 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2026 OpenLink Software